Phase III trial

Boehringer Ingelheim's survodutide achieved 16.6% average weight loss in Phase III trials, with 85.1% of patients hitting ≥5% reduction targets, supporting obesity and MASH treatment potential.

Greenwich LifeSciences reports significant immune response gains in Phase III FLAMINGO-01 trial for GLSI-100 breast cancer recurrence prevention, showing 70-80% recurrence reduction.

MediWound to present new EscharEx clinical and preclinical data at major wound care conferences in April-May 2026, advancing Phase III trial progress and supporting expansion into new indications.

RenovoRx ($RNXT) earns Fast Company recognition as #10 innovative medical device firm, with $1.1M RenovoCath sales and Phase III pancreatic cancer trial advancing toward mid-2026 enrollment completion.

Ultragenyx faces class action alleging misrepresentation of setrusumab trial data using improper Phase II benchmarks. Investors from August 2023–December 2025 may be eligible to join the suit.

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.

Class action lawsuit filed against Ultragenyx Pharmaceutical alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta treatment based on flawed trial comparisons.

Class action filed against Ultragenyx ($RARE) alleging misrepresented setrusumab trial data. Investors purchasing August 2023-December 2025 may recover damages.

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.